MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

1.93 -3.98

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.9

Максимум

1.96

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5.9M 14M
Предишно отваряне	5.91
Предишно затваряне	1.93

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.01.2026 г., 00:16 ч. UTC

Придобивния, сливания и поглъщания

Edwards Lifesciences Drops Merger With JenaValve

11.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Gold Rises Amid Geopolitical Risks -- Market Talk

11.01.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Rises Amid Middle East Tensions -- Market Talk

11.01.2026 г., 23:25 ч. UTC

Печалби

Stock Futures Drift Lower With Bank Earnings, CPI on Tap -- Barrons.com

11.01.2026 г., 22:05 ч. UTC

Пазарно говорене

Iron Ore Outlook Weighed by Soft China Steel Markets, Rising Supply -- Market Talk

10.01.2026 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Copper Is the Prize in Mining Megadeals -- WSJ

10.01.2026 г., 09:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

10.01.2026 г., 09:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

10.01.2026 г., 09:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.01.2026 г., 22:18 ч. UTC

Пазарно говорене

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.01.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9.01.2026 г., 20:39 ч. UTC

Пазарно говорене

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9.01.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9.01.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9.01.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9.01.2026 г., 20:15 ч. UTC

Пазарно говорене

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9.01.2026 г., 20:07 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.01.2026 г., 20:07 ч. UTC

Пазарно говорене

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9.01.2026 г., 19:58 ч. UTC

Придобивния, сливания и поглъщания

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9.01.2026 г., 19:42 ч. UTC

Пазарно говорене

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9.01.2026 г., 19:38 ч. UTC

Придобивния, сливания и поглъщания

Wolters Kluwer Acquires StandardFusion >WTKWY

9.01.2026 г., 19:31 ч. UTC

Печалби

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9.01.2026 г., 19:28 ч. UTC

Печалби

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9.01.2026 г., 18:30 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9.01.2026 г., 18:23 ч. UTC

Пазарно говорене

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.